Chimeric Antigen Receptor (CAR)-T cell therapy is a therapeutic approach whereby T-cells are engineered with a synthetic receptor for increased tumor targeting specificity and tumor cytotoxicity.
The central image depicts currently used strategies for clinical targeting of TGF-β. Below are methods applicable from preclinical screening to clinical practice, including using humanized mouse ...
IO Biotech presents preclinical data supporting dual-antigen and TGF-β-targeted vaccines for enhancing anti-tumor immunity at AACR 2025. IO Biotech presented new preclinical data at the AACR Annual ...
Prostate cancer (PCa) remains a significant global health challenge, with rising morbidity rates and poor prognosis associated with advanced stages ...
The diagram highlights: clonal tumor populations comprising multiple molecular subtypes, contributing to BTCs heterogeneity. Distinct TME components, including: cancer-associated fibroblasts (CAFs) ...
Gastrointestinal (GI) cancers, such as colorectal, gastric, and pancreatic cancers, are among the most prevalent and deadly worldwide. Despite advances in treatment, these cancers often remain ...
70.6% Partial Response and 82.4% Disease Control Rate Observed in Interim Phase II Data SEONGNAM, South Korea, Nov. 10, 2025 /PRNewswire/ -- On Friday, 7 November (local time) at the Society for ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results